<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02892903</url>
  </required_header>
  <id_info>
    <org_study_id>RHM CAR0498</org_study_id>
    <nct_id>NCT02892903</nct_id>
  </id_info>
  <brief_title>In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?</brief_title>
  <acronym>RIPCORD 2</acronym>
  <official_title>A Randomised Controlled Trial to Compare Routine Pressure Wire Assessment With Conventional Angiography in the Management of Patients With Coronary Artery Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Liverpool Heart and Chest Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Southampton NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised controlled trial to compare two strategies for the investigation of coronary
      artery disease at the time of angiography. Patients will be randomised to conventional
      angiography or additional, routine pressure wire assessment - measuring fractional flow
      reserve (FFR) - in all main vessels judged as being of sufficient vessel calibre to allow
      percutaneous coronary intervention (PCI) (experimental arm).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will recruit patients undergoing angiography for the investigation of stable angina
      or for the assessment of a recent, but stabilised, non-ST elevation acute coronary syndrome
      event. Eligible patients who provide written informed consent will be randomised to
      conventional angiography or additional, routine pressure wire assessment - measuring
      fractional flow reserve (FFR) - in all main vessels judged as being of sufficient vessel
      calibre to allow percutaneous coronary intervention (PCI) (experimental arm). The study
      pragmatic design allows investigators to conduct all diagnostic and therapeutic management in
      accordance with prevailing best practice patterns. Study outcome measures will examine
      resource utilisation, patient reported quality of life and clinical events at 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Economic Outcome Measure</measure>
    <time_frame>One year</time_frame>
    <description>Resource utilisation as determined by hospital care costs at one year; All hospital admissions will be tracked using national hospital episode statistics; the cost of each episode will be derived from a cost model using standard UK tariffs. This analysis will compare the mean (or median) of the total hospital costs recorded for each patient over the 12 month follow-up period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Quality of Life Outcome Measure</measure>
    <time_frame>One year</time_frame>
    <description>Patient reported quality of life at one year using the EQ-5D health questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Management strategy information</measure>
    <time_frame>Reported once: Single declaration at index procedure after randomisation</time_frame>
    <description>· Proportion of vessels deemed to demonstrate flow-limiting disease and targeted for revascularisation in the declared initial management strategy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Management strategy information</measure>
    <time_frame>Reported once: Single declaration at index procedure after randomisation</time_frame>
    <description>· Proportion of patients scheduled for management with medical therapy, percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) in the declared initial management strategy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina symptoms</measure>
    <time_frame>One year</time_frame>
    <description>• Angina symptoms as reported by the research team after the 12 month contact, described by Canadian Cardiovascular Society Grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina symptoms</measure>
    <time_frame>One year</time_frame>
    <description>• Angina symptoms as reported by the patient with private completion of a screening form at 12 months, described by Canadian Cardiovascular Society Grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalisation events</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospital days</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation events</measure>
    <time_frame>One year</time_frame>
    <description>Hospitalisation events coded as cerebro-vascular accident (CVA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation events</measure>
    <time_frame>One year</time_frame>
    <description>Hospitalisation events coded as myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation events</measure>
    <time_frame>One year</time_frame>
    <description>Hospitalisation events coded as Coronary revascularisation. This analysis will involve a pre-specified subgroup analysis of:
Planned revascularisation - if declared as the index strategy.
All additional revascularisation events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Chest Pain</condition>
  <condition>Stable Angina</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Non ST Segment Elevation Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Conventional angiography</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine angiography will be performed according to local best practice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine Measurement of FFR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional investigation with the measurement of FFR in all major vessels</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Routine Measurement of FFR</intervention_name>
    <description>FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow &lt;3 will not be examined but will be 'awarded' an FFR value of 0.5</description>
    <arm_group_label>Routine Measurement of FFR</arm_group_label>
    <other_name>Pressure wire assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        · Inclusion criteria

        o Outline Initial Inclusion Criteria (before entry to cath lab):

        Patient scheduled for coronary angiography for the:

          -  Elective investigation of known or suspected coronary artery disease OR

          -  Urgent investigation of a recent but stabilised, non-ST elevation acute coronary
             syndrome event

             o Outline Angiographic Inclusion Criterion (after angiography):

          -  Presence of significant coronary disease defined as:

        Any stenosis &gt;30% reduction in luminal diameter, by visual estimate, in at least one vessel
        (main or branch) of sufficient calibre to permit the potential performance of PCI -
        approximately 2.25 mm diameter.

          -  Key Exclusion Criteria

               -  Screening phase exclusion criteria:

                    -  ≤ 18 years of age

                    -  Previous enrolment in this trial

                    -  Currently enrolled into another study unless co-enrolment approved by Chief
                       Investigator (CI) and the clinical trials unit (CTU)

                    -  Inability to provide informed consent

                    -  Residence outside the United Kingdom (UK) or other issues limiting the
                       ability to secure clinical follow-up data to one year

                    -  Non-cardiac pathology that may limit survival in the next year

                    -  Clear contraindication to potential future management with CABG or PCI
                       (patients should be a potential candidate for medical therapy or
                       revascularisation with either PCI or surgery)

                    -  Heart valve disease of sufficient import to consider valve replacement or
                       other intervention as part of an index management strategy

                    -  Hypertrophic cardiomyopathy

                    -  Previous coronary artery surgery of any type

                    -  Known chronic renal impairment with a current estimated glomerular
                       filtration rate (eGFR) of &lt; 45

                    -  Anaemia with a current measured haemoglobin of &lt; 100

                    -  Angiography performed in the context of an ST elevation myocardial
                       infarction event

                    -  Any patient who at the time of planned angiography manifests haemodynamic
                       instability, or recurrent sustained ventricular arrhythmia, or Mobitz type
                       II or complete heart block

                    -  Any patient who at the time of planned angiography manifests unstable chest
                       pain symptoms at rest or has required the continuing use of intravenous
                       nitrates or regular opioid analgesia to control symptoms

                    -  Continuing use of intravenous glycoprotein 2b/3a (GP2b3a) agents before
                       entry to the catheterisation laboratory

                    -  Known intolerance, hypersensitivity or contraindication to adenosine -
                       including significant reversible airways disease

                    -  Additional investigations planned (or deemed likely to be required) for the
                       assessment of myocardial ischaemia or viability. Examples of proposed tests
                       that would constitute an exclusion criterion would include, but are not
                       limited to, exercise tolerance testing, stress echocardiography, cardiac MRI
                       viability or perfusion scanning or nuclear myocardial perfusion scanning.

                    -  Active bleeding at the time of planned index angiography

                    -  Pregnant women

               -  Angiographic phase exclusion criteria:

                    -  Single vessel occlusive coronary disease (TIMI flow &lt;3) as sole disease

                    -  Patient not suitable for the immediate performance of a pressure wire
                       assessment of all major vessels for any reason, for example:

                         -  Patient discomfort

                         -  Change in the clinical condition or complication of angiography
                            requiring termination of the procedure or immediate intervention

                         -  Significant use of radiographic contrast or X-Ray exposure during the
                            initial angiography

                         -  Inadequate angiographic images or failure to intubate any of the
                            coronary vessels

                         -  Aorto-ostial disease that would preclude accurate assessment of FFR

                         -  Insufficient laboratory time

                         -  Uncertain availability of key clinical and trial staff

                         -  PW use in coronaries declared unsafe (e.g. tight or long disease)

                         -  PW use in coronaries declared unsuitable (e.g. distal disease or
                            complete cross-filling)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Curzen, BM PhD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Southampton NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rod H Stables, MA, DM, BM BCH, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liverpool Heart and Chest Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rodney H Stables, MA, DM, BM BCH, FRCP</last_name>
    <phone>+44 151 600 1489</phone>
    <email>rod.stables@lhch.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mostafa M Elguindy, MBChB, MSc</last_name>
    <phone>+44 0151 254 3040</phone>
    <email>mostafa.elguindy@lhch.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital - The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</name>
      <address>
        <city>Bournemouth</city>
        <state>Dorset</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Horler</last_name>
      <phone>0120 270 4514</phone>
      <email>Cardiac.Research@rbch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Peter O'Kane, BSc MBBS MRCP MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals NHS Trust</name>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Skipper</last_name>
      <phone>01273 696955</phone>
      <phone_ext>63861/4049</phone_ext>
      <email>Nicola.skipper@bsuh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Andrew MsGreggor</last_name>
      <phone>01273 696955</phone>
      <phone_ext>64049</phone_ext>
      <email>andrew.mcgregor@bsuh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>David Hildick-Smith, MD, FRCP, FSCAI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <state>Hampshire</state>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Cunnington</last_name>
      <phone>0239 228 6000</phone>
      <phone_ext>3876</phone_ext>
      <email>Anna.Cunnington@porthosp.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Serena Howe</last_name>
      <phone>0239 228 6000</phone>
      <phone_ext>3295</phone_ext>
      <email>Serena.Howe2@porthosp.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander Hobson, FRCP MBBS BSc MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital - University Hospitals Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe Nicholas</last_name>
      <phone>0238 120 8538</phone>
      <email>zoe.nicholas@uhs.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Sam Gough</last_name>
      <phone>0238 120 8538</phone>
      <email>Sam.Gough@uhs.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Nicholas Curzen, BM PhD FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Blackburn Teaching Hospital - East Lancashire Hospitals NHS Trust</name>
      <address>
        <city>Blackburn</city>
        <state>Lancashire</state>
        <zip>BB2 3HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen N Davies</last_name>
      <phone>+44 01254 732649</phone>
      <phone_ext>82649</phone_ext>
      <email>karen.davies2@elht.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Hawa Desai</last_name>
      <phone>+44 01254 732649</phone>
      <email>hawa.desai@elht.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Scot Garg, MBChB, MRCP, PhD (Hons), FESC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L14 3PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Barton</last_name>
      <phone>01516001672</phone>
      <email>Janet.Barton@lhch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rodney H Stables, MA, DM, BM BCH, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital - Newcastle Hospitals</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Northumberland</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Jones</last_name>
      <phone>0191 2448939</phone>
      <email>Samantha.Jones@nuth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Azfar Zaman, BSc, MBChB, MD, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's Mill Hospital - Sherwood Forest Hospitals NHS Foundation Trust</name>
      <address>
        <city>Mansfield</city>
        <state>Nottinghamshire</state>
        <zip>NG17 4JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Shelton</last_name>
      <phone>01623 622515</phone>
      <phone_ext>6304</phone_ext>
      <email>Sarah.Shelton@sfh-tr.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lynne Allsop</last_name>
      <phone>01623 622515</phone>
      <phone_ext>3990</phone_ext>
      <email>lynne.allsop@sfh-tr.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Aftab Jan, MBBS, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Hospital - Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Burton</last_name>
      <phone>0115 9691169</phone>
      <email>jane.burton@nuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sachin Jadhav, MBChB(Hons) MD FRCP(glasg)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G81 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Kelly</last_name>
      <phone>0141 951 5176</phone>
      <email>joanne.kelly@goldenjubilee.scot.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Anna O'Donnell</last_name>
      <phone>0141 951 4701</phone>
      <email>anna.odonnell@goldenjubilee.scot.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Colin Berry, BSc, MB.ChB, PhD, FRCP, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern General Hospital - Sheffield Teaching Hospitals</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Middle</last_name>
      <phone>+44 11427 15779</phone>
      <phone_ext>15779</phone_ext>
      <email>janet.middle@sth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Shay Willoughby</last_name>
      <phone>+44 11427 15779</phone>
      <email>shay.willoughby@sth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Julian Gunn, MA MB BChir MD MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital - University Hospitals of North Midlands</name>
      <address>
        <city>Stoke-on-Trent</city>
        <state>Staffordshire</state>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Delaney</last_name>
      <phone>01782 672779</phone>
      <email>jane.delaney@uhnm.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Ian Massey</last_name>
      <email>ian.massey@uhnm.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Mamas Mamas, BM BCh, MA, DPhil, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Nilsson</last_name>
      <phone>01213714624</phone>
      <email>annette.nilsson@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sohail Khan, BSc (Hons), MB ChB, MD, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pinderfields Hospital - The Mid Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Wakefield</city>
        <state>West Yorkshire</state>
        <zip>WF1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Exley</last_name>
      <phone>01924 541808</phone>
      <email>donna.exley@midyorks.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Judith Wright</last_name>
      <phone>01924 541808</phone>
      <email>Judith.Wright2@midyorks.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Dwayne Conway, MD, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital - Hull and East Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Hull</city>
        <state>Yorkshire</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Chaytor</last_name>
      <phone>01482 626767</phone>
      <email>lisa.chaytor@hey.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Angela Hoye, MB ChB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary - Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>Yorkshire</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Somers</last_name>
      <phone>0113 3928483</phone>
      <email>kathryn.somers@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Stephen Wheatcroft, BS(Hons) MBChB(Hons) PhD FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Heart Institute - University Hospitals Bristol NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isobel Sullivan</last_name>
      <phone>0117 342 1141</phone>
      <phone_ext>6938</phone_ext>
      <email>isobel.sullivan@uhbristol.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Bowles</last_name>
      <email>ruth.bowles@uhbristol.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Johnson, BSc MBBS MRCP MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Zir LM, Miller SW, Dinsmore RE, Gilbert JP, Harthorne JW. Interobserver variability in coronary angiography. Circulation. 1976 Apr;53(4):627-32.</citation>
    <PMID>1253383</PMID>
  </reference>
  <reference>
    <citation>White CW, Wright CB, Doty DB, Hiratza LF, Eastham CL, Harrison DG, Marcus ML. Does visual interpretation of the coronary arteriogram predict the physiologic importance of a coronary stenosis? N Engl J Med. 1984 Mar 29;310(13):819-24.</citation>
    <PMID>6700670</PMID>
  </reference>
  <reference>
    <citation>De Bruyne B, Baudhuin T, Melin JA, Pijls NH, Sys SU, Bol A, Paulus WJ, Heyndrickx GR, Wijns W. Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography. Circulation. 1994 Mar;89(3):1013-22.</citation>
    <PMID>8124786</PMID>
  </reference>
  <reference>
    <citation>Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J Koolen JJ, Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996 Jun 27;334(26):1703-8.</citation>
    <PMID>8637515</PMID>
  </reference>
  <reference>
    <citation>Berger A, Botman KJ, MacCarthy PA, Wijns W, Bartunek J, Heyndrickx GR, Pijls NH, De Bruyne B. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. J Am Coll Cardiol. 2005 Aug 2;46(3):438-42.</citation>
    <PMID>16053955</PMID>
  </reference>
  <reference>
    <citation>Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009 Jan 15;360(3):213-24. doi: 10.1056/NEJMoa0807611.</citation>
    <PMID>19144937</PMID>
  </reference>
  <reference>
    <citation>Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van't Veer M, Bär F, Hoorntje J, Koolen J, Wijns W, de Bruyne B. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007 May 29;49(21):2105-11. Epub 2007 May 17.</citation>
    <PMID>17531660</PMID>
  </reference>
  <reference>
    <citation>Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, Bornschein B, van't Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, De Bruyne B; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010 Jul 13;56(3):177-84. doi: 10.1016/j.jacc.2010.04.012. Epub 2010 May 28.</citation>
    <PMID>20537493</PMID>
  </reference>
  <reference>
    <citation>De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012 Sep 13;367(11):991-1001. doi: 10.1056/NEJMoa1205361. Epub 2012 Aug 27. Erratum in: N Engl J Med. 2012 Nov;367(18):1768. Mobius-Winckler, Sven [corrected to Möbius-Winkler, Sven].</citation>
    <PMID>22924638</PMID>
  </reference>
  <reference>
    <citation>Longman K, Curzen N. Should ischemia be the main target in selecting a percutaneous coronary intervention strategy? Expert Rev Cardiovasc Ther. 2013 Aug;11(8):1051-9. doi: 10.1586/14779072.2013.814856. Review.</citation>
    <PMID>23984928</PMID>
  </reference>
  <reference>
    <citation>Toth G, Hamilos M, Pyxaras S, Mangiacapra F, Nelis O, De Vroey F, Di Serafino L, Muller O, Van Mieghem C, Wyffels E, Heyndrickx GR, Bartunek J, Vanderheyden M, Barbato E, Wijns W, De Bruyne B. Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. Eur Heart J. 2014 Oct 21;35(40):2831-8. doi: 10.1093/eurheartj/ehu094. Epub 2014 Mar 18.</citation>
    <PMID>24644308</PMID>
  </reference>
  <reference>
    <citation>Curzen N, Rana O, Nicholas Z, Golledge P, Zaman A, Oldroyd K, Hanratty C, Banning A, Wheatcroft S, Hobson A, Chitkara K, Hildick-Smith D, McKenzie D, Calver A, Dimitrov BD, Corbett S. Does routine pressure wire assessment influence management strategy at coronary angiography for diagnosis of chest pain?: the RIPCORD study. Circ Cardiovasc Interv. 2014 Apr;7(2):248-55. doi: 10.1161/CIRCINTERVENTIONS.113.000978. Epub 2014 Mar 18.</citation>
    <PMID>24642999</PMID>
  </reference>
  <reference>
    <citation>Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Glob Heart. 2012 Dec;7(4):275-95. doi: 10.1016/j.gheart.2012.08.001. Epub 2012 Sep 26.</citation>
    <PMID>25689940</PMID>
  </reference>
  <reference>
    <citation>Weintraub WS, Mahoney EM, Zhang Z, Chu H, Hutton J, Buxton M, Booth J, Nugara F, Stables RH, Dooley P, Collinson J, Stuteville M, Delahunty N, Wright A, Flather MD, De Cock E. One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Heart. 2004 Jul;90(7):782-8.</citation>
    <PMID>15201249</PMID>
  </reference>
  <reference>
    <citation>Zhang Z, Mahoney EM, Stables RH, Booth J, Nugara F, Spertus JA, Weintraub WS. Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial. Circulation. 2003 Oct 7;108(14):1694-700. Epub 2003 Sep 15.</citation>
    <PMID>12975252</PMID>
  </reference>
  <reference>
    <citation>SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet. 2002 Sep 28;360(9338):965-70.</citation>
    <PMID>12383664</PMID>
  </reference>
  <reference>
    <citation>Van Belle E, Rioufol G, Pouillot C, Cuisset T, Bougrini K, Teiger E, Champagne S, Belle L, Barreau D, Hanssen M, Besnard C, Dauphin R, Dallongeville J, El Hahi Y, Sideris G, Bretelle C, Lhoest N, Barnay P, Leborgne L, Dupouy P; Investigators of the Registre Français de la FFR–R3F. Outcome impact of coronary revascularization strategy reclassification with fractional flow reserve at time of diagnostic angiography: insights from a large French multicenter fractional flow reserve registry. Circulation. 2014 Jan 14;129(2):173-85. doi: 10.1161/CIRCULATIONAHA.113.006646. Epub 2013 Nov 19.</citation>
    <PMID>24255062</PMID>
  </reference>
  <reference>
    <citation>Henderson R, Lee L. The epidemiology and pathophysiology of coronary artery disease. Chapter 1 in The Oxford Textbook of Interventional Cardiology. Eds: Redwood, Curzen, Thomas. Oxford University Press 2010.</citation>
  </reference>
  <reference>
    <citation>Muller O, De Bruyne B. Coronary physiology in clinical practice. Chapter 9 in in The Oxford Book of Interventional Cardiology. Eds: Redwood, Curzen, Thomas. Oxford University Press 2010.</citation>
  </reference>
  <reference>
    <citation>Chest Pain of Recent Onset. NICE Guidance CG95, 2010. https://www.nice.org.uk/guidance/CG95</citation>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fractional flow reserve (FFR)</keyword>
  <keyword>Pressure wire (PW)</keyword>
  <keyword>Coronary angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

